-
Biodel receives complete response letter for Linjeta
DANBURY, Conn. The Food and Drug Administration has turned down an application for an insulin product made by Biodel, Biodel said.
The drug maker announced that it received a complete response letter from the FDA for Linjeta (human insulin [rDNA origin]) for the treatment of Type 1 and Type 2 diabetes.
-
Tolerx's scientific advisory board to advance Type 1 diabetes research
CAMBRIDGE, Mass. A company that develops drugs for treating autoimmune diseases and cancer has created a scientific advisory board as part of its efforts to create treatments for Type 1 diabetes.
Tolerx said the four-member board would support the development of its lead drug candidate, otelixizumab, and guide future research and development in the Type 1 diabetes area.